一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括BL-M07D1；DS-8201，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BL-M07D1；DS-8201 · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
公开的入选条件
- 1. Voluntarily sign the informed consent form and agree to comply with the protocol requirements；
- 2. Female patients aged ≥18 years and ≤75 years at the time of signing the informed consent form；
- 3. Life expectancy ≥12 weeks；
- 4. Locally recurrent or metastatic breast cancer that is hormone receptor (HR)-positive and HER2-low expressing；
- 5. Provide adequate and recent tumor tissue specimens for central laboratory testing of HER2, HR, and other biomarkers as required；
- 6. Meet the prior treatment requirements as specified in the protocol；
- 7. Have at least one measurable target lesion per RECIST v1.1 criteria；
- 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07678957；登记信息更新于 2026-09-14。